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Diseases of the gastrointestinal tract are com-
mon among those who are HIV-infected.
Sometimes the first clue that a previously undi-
agnosed inmate/patient is HIV-infected is the
presence of an HIV-associated gastrointestinal
condition. These conditions can lead to signifi-
cant morbidity including pain, difficulty swallow-
ing, diarrhea, and weight loss. Early diagnosis
and treatment can substantially improve the
lives of those who are
afflicted by these condi-
tions. Although identify-
ing the specific etiology
of a patient's symptoms
can be challenging, a
methodical approach can
usually identify a treat-
able condition. This arti-
cle focuses on some of
the most common abnor-
malities of the gastroin-
testinal system that correctional health care
providers are likely to encounter among their
HIV-infected patients. 
Oral Lesions
The most common HIV-associated oral condi-
tion is candidiasis, or thrush. Thrush is usually
found in those with advanced immunodeficien-
cy, generally in patients with a CD4+ T cell
count less than 300 cells/mm3. Oral candidiasis
is associated with progression to AIDS, and the
presence of thrush in someone who is not
known to be HIV infected should prompt a rec-
ommendation for HIV testing. Thrush most
commonly appears as a white cheesy exudate
that can be easily wiped off. Alternatively,
thrush can present as erythema without exu-
dates. The lesions are most commonly seen on
the soft palate and tongue.  Mild thrush can be
treated with topical nystatin or clotrimazole
troches. In more severe cases, oral fluconazole
is highly effective. In cases of thrush caused by
azole-resistant Candida, a higher dose of the
azole can sometimes overcome resistance. If
treatment with an azole drug is unsuccessful, a
short course of either amphotericin swish and
swallow or intravenous amphotericin is some-
times required. Candida can also cause angu-
lar cheilitis, or fissures located at the angle of
the mouth. These lesions also occur in the set-
ting of anemia or vitamin deficiency, but are
more commonly due to Candida and typically
respond promptly to oral azole therapy or even
topical nizoral cream.   
Oral hairy leukoplakia (OHL) generally pre-
sents as filamentous or
hairy projections on the lat-
eral borders of the tongue.
The lesions are usually
poorly demarcated and
can have a flattened
appearance. In contrast to
thrush, the lesion of OHL
cannot be brushed off.
Thought to be due to
Epstein-Barr virus, the
lesions are asymptomatic
nd are generally of only cosmetic importance.
OHL sometimes responds to acyclovir or vala-
cyclovir, although probably the best treatment
is HAART-induced immune reconstitution. As
with thrush, OHL is highly predictive of HIV
infection.
Aphthous ulcers are common and often severe
in those who are HIV infected. Ulcers are tradi-
tionally classified as minor (<10mm) or major
(>10mm) in size, and can be single or multiple.
The lesions are typically painful, well-demarcat-
ed ulcerations that can be either shallow or
deep. Ulcers can be found on the buccal or
labial mucosa, tongue, soft palate, or pharynx.
Not uncommonly, the patient will have a tender
adjacent submandibular node. Aphthous ulcers
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GASTROINTESTINAL COMPLICATIONS OF HIV DISEASE
Joseph Bick*, MD, Chief Medical Officer, California Medical Facility, California Department of Corrections
“Although identifying the 
specific etiology of a patient's
symptoms can be 
challenging, a methodical
approach can usually identify
a treatable condition.”
are of unknown etiology. Some clinicians
recommend treatment with topical suspen-
sions of tetracycline with or without nystatin
or hydrocortisone, while others recom-
mend topical Kenalog® in Orabase, which
is a paste that will stick to the wet surfaces
of the mouth and form a protective film over
the mouth ulcer.  Minor aphthae usually
heal without scarring in <10 days regard-
less of therapy. Perhaps the best approach
is analgesics such as ibuprofen and, prior
to meals, topical viscous lidocaine.
Avoidance of acidic foods such as toma-
toes and citrus is also useful while lesions
are present. Major aphthae can be more
painful and take longer to heal. Aphthae
can also present in a herpetiform pattern,
with multiple small ulcerative lesions. Oral
lesions that do not heal within two weeks or
those that are accompanied by systemic
signs such as fever should be biopsied to
rule out other etiologies such as deep fun-
gal infection or malignancy. Single shallow
painless ulcerations can be due to syphilis
(condyloma lata), and should be screened
for with a rapid plasma reagin (RPR) test.  
Warts can be  found on the lips or in the
oral cavity and are typically painless.
Caused by human papillomavirus, lesions
can be either flat or cauliflower shaped and
are often multiple in number. Lesions can
be removed with a scalpel, by electro-
surgery, laser ablation, or liquid nitrogen. If
the lesion is flat and located on the tongue,
consider other potential causes, such as
syphilis.  
Kaposi's sarcoma (KS) can be found any-
where in the GI tract.  When found in the
oral cavity, KS is most commonly red, blue,
or purple in color and can be either macu-
lar or nodular. Lesions are most commonly
found on the hard palate, but can also be
seen on the gingiva or oropharynyx. The
diagnosis is made by histologic examina-
tion of tissue obtained by biopsy. The most
effective treatment is immune reconstitu-
tion by HAART, but in those for whom this
is not possible intralesional chemothera-
peutic agents such as vinblastine have
been used.  
Esophageal Lesions
Disease involving the esophagus is com-
mon in advanced HIV infection, and is most
commonly due to Candida. Patients with
candidal esophagitis usually have orpha-
ryngeal involvement as well and present
with dysphagia and odynophagia. In
patients with a typical presentation, most
clinicians empirically treat  to cover
Candida and reserve further evaluation for
those who fail to respond. Oral fluconazole
(200 mg on day one followed by 100 mg
daily for two weeks) is usually highly effec-
tive, although azole resistance can be pre-
sent at baseline or develop while on treat-
ment. Intravenous fluconazole or low-dose
amphotericin B (0.3mg/kg/day) can be
used in patients who cannot swallow.
Voriconazole may be effective in some
cases of fluconazole resistant Candida.
Caspofungin, an antifungal in the
echinocandin class, has also shown clini-
cal activity in some cases of azole-resistant
candidal infections.
In cases of esophagitis  that fail to respond
to antifungal therapy, endoscopy with biop-
sy is required to rule out other etiologies
such as herpes simplex virus, (HSV)
cytomegalovirus, (CMV), malignancy, or
aphthous ulcerations. Patients with CMV
esophagitis commonly have systemic
symptoms such as fever, nausea, emesis,
diarrhea, abdominal pain, and weight loss.
Biopsy reveals CMV infected cells with
intranuclear inclusion bodies. CMV
esophagitis can be treated intravenously
with ganciclovir (5mg/kg q 12 hours for 14
days) or foscarnet (60mg/kg q 8 hours for
14 days). Ganciclovir can lead to myelo-
suppression, while foscarnet can cause
renal insufficiency, electrolyte distur-
bances, and penile ulcerations. 
Esophageal HSV can present with
odynophgia, dysphagia, retrosternal pain,
nausea, and emesis. Untreated patients
can develop tracheoesophageal fistulas,
necrosis, stricture, or hemorrhage. Biopsy
demonstrates cytoplasmic inclusion bod-
ies, ground glass appearance of nuclei,
and multinucleated giant cells. HSV
responds to intravenous acyclovir. 
Major aphthae involving the esophagus
can persist and be significantly debilitating.
In some cases, systemic steroids or oral
thalidomide is useful in hastening healing.
Diarrhea
Worldwide, diarrhea is the most common
cause of morbidity and mortality among
those who are HIV-infected. Diarrhea can
be caused by bacterial, viral, or parasitic
infections, or by a medication. In many
cases, a careful search can identify a treat-
able etiology of the patient's diarrhea.
There is little data specifically addressing
the etiologies of diarrhea among the incar-
cerated. One would expect that the fre-
quency of some pathogens would differ
among those recently incarcerated as
compared to those who have been institu-
tionalized for an extended period of time.
Likewise, the causes of diarrhea among
foreign-born inmates and those who have
traveled outside of the United States may
differ from those who have never left the
country.  
The evaluation of a patient with  diarrhea
begins with a thorough history and physical
examination.  Patients may use the word
diarrhea to describe anything from a rectal
discharge, to occasional loose stools, to
frequent large volume bowel movements.
Additionally, acute self-limited diarrhea
occurs frequently in otherwise healthy
adults.  Diarrhea that has been present for
years with little if any weight loss is more
likely to be due to irritable bowel, inflam-
matory bowel, or lactose intolerance than
to an infectious etiology. In patients with
advanced immunodeficiency, fever, and
anemia, opportunistic infections such as
those caused by  Mycobacterium avium
complex (MAC) and  CMV must be consid-
ered. Medications or dietary changes are
often an overlooked cause of changes in
bowel frequency or consistency. In jails and
prisons, regulated access to toilets and toi-
let paper can cause those who experience
medication-induced diarrhea to adhere
poorly to prescribed treatments. Drugs that
commonly cause a change in bowel motili-
ty include laxatives, antacids, cardiac med-
ications, some psychiatric medications,
and antiretroviral agents such as ddI, riton-
avir and nelfinavir. Antibiotics can alter
testinal flora and lead to loose stools. 
In those who present with symptoms of
greater than one-week duration associated
with weight loss, fever, dehydration, or
bloody stools, diagnostic studies are indi-
cated. The intensity of the work-up is sub-
ject to debate, but most would agree that a
stepwise approach is usually appropriate in
those who are not critically ill.  Generally, in
HIV infected patients it is most appropriate
to begin with evaluation of stool specimens
for presence of ova, parasites, Clostridium
difficile toxin, Salmonella, Shigella,
Campylobacter, E. coli 0157 H7,
Cryptosporidium, and Microsporidia. To
increase the yield, it is recommended to
send three separately collected specimens
for ova and parasite analysis. If the patient
is febrile, blood cultures for bacteria should
be collected. In those with advanced
immunodeficiency (CD4 <75/mm3) blood
cultures for mycobacteria are also indicat-
ed. If stool studies and blood cultures fail to
identify an etiology, flexible sigmoidoscopy
or colonoscopy with biopsy should be per-
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Dear Correctional Colleagues:
In this month's issue of HEPP, the lead article by Dr. Joseph Bick describes the most com-
mon HIV-related GI conditions, and how to diagnose and manage patients with these condi-
tions. As Dr. Bick points out, the most important first step in the evaluation of GI complaints
is a thorough history. The terms diarrhea, constipation and "stomach ache" denote different
things to different people. Accordingly, clarifying what the patient means by his or her com-
plaints is an important component to any evaluation. GI disease is common among persons
with HIV infection. Luckily, most of the infectious causes are treatable and conditions not
readily treated with antibiotics may respond to immune reconstitution with HAART. 
Infections are the etiology for many of the HIV-related GI disturbances. As Dr. Bethany
Weaver illustrates in this month's case study, the causative organisms can be myriad. In
crowded congregate settings such as correctional facilities, food-related outbreaks are rela-
tively more common. Any potential clustering of illness in such a setting should raise suspi-
cions of an outbreak and appropriate investigation and control measures should take place.
While those with HIV infection may not be at increased risk of acquiring pathogens that
cause most foodborne illnesses such as Salmonella or Campylobacter, consequences of
such an outbreak can be more severe in an immunocompromised host.
In Part II of the highlights from the Eleventh Annual Conference on Retroviruses and
Opportunistic Infections (CROI) held in San Francisco. Dr. Rick Altice reports on two thera-
peutic trials that examined use of once-daily dosing of ritonavir-boosted PI-containing regi-
mens of highly effective ART. Simplifying regimens to once-daily dosing will be an important
step toward improved patient adherence that could potentially lead to improved outcomes
and decreased development of viral resistance. With the continued development of medica-
tions with longer half lives and pharmacoenhancement with drug combinations, hopefully
more once-daily regimens will soon be a available. 
We strive to present topics that our readers find useful and interesting and pertinent to cor-
rectional settings. If you have an idea of a topic you think should be addressed in HEPP
Report, we welcome your thoughts or suggestions.
Sincerely,
Renee Ridzon, MD
Letter from the Editor
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4formed. Biopsy specimens should be
cultured for Salmonella, Shigella,
Campylobacter, mycobacteria, CMV, and
HSV. Histologic evaluation should include
staining for mycobacteria, fungi, proto-
zoans, and viral inclusions.
Bacterial causes of diarrhea
In non-incarcerated HIV-infected persons
in the U.S., the most common bacterial
causes of diarrhea are Salmonella, C. diffi-
cile, MAC, Shigella, and Campylobacter.
The overall incidence of bacterial colitis
has been reduced in this country by the
widespread use of trimethoprim/sul-
famethoxazole (TMP/FMX) for
Pneumocystis prophylaxis.
Fever is more commonly seen in
Salmonella infection than in other bacterial
cause of diarrhea. Blood in the stool sug-
gest Shigella or Campylobacter rather than
Salmonella. Among those infected with
HIV,  Salmonella is more likely to lead to
bacteremic disease and to relapse after
treatment. Predictors of relapse include
septicemia and low CD4 lymphocyte
counts. Salmonella can be treated with
TMP/FMX, a quinolone, or azithromycin.
Among those with CD4 counts less than 50
cells/mm3 who have experienced relapsed
infection with Salmonella, ongoing mainte-
nance therapy with ciprofloxacin should be
considered. If bacterial colitis is suspected,
medications that decrease bowel motility
such as diphenoxylate, loperamide, pare-
goric, and tincture of opiates should be
avoided because they have been associat-
ed with the development of toxic mega-
colon or prolongation of infection.
Clustering of cases of bacterial diarrhea
caused by Salmonella, Shigella, or E. Coli
0157H7 may indicate a food borne out-
break or person-to-person transmission
and should lead to an investigation.
Infection with C. difficile can lead to diar-
rhea in patients with AIDS. Both receiving
antibiotics and being hospitalized are asso-
ciated with an increased risk for C. difficile
infection. Diagnosis can be made by the
detection of C. difficile toxin in stool. The
first line treatment is oral metronidazole at
a dose of 500 mg by mouth 3X/day for 10-
14 days. Because of the concern for
encouraging the development of resistant
organisms, oral vancomycin should be
reserved for only  those patients who fail to
respond to metronidazole. 
Disease due to  MAC is uncommon among
those who have a CD4 lymphocyte count of
>100/mm3 and those who are taking
macrolide prophylaxis. Among those with
severe immunosuppression, disseminated
MAC can cause diarrhea with fever,
sweats, anemia, neutropenia, weight loss,
and hepatosplenomegaly. Stool or blood
cultures for acid-fast bacilli (AFB) can con-
firm the diagnosis. While culture of the
organism from a tissue specimen is the
gold standard for diagnosis, endoscopic
biopsy showing foamy macrophages and
acid-fast organisms can be used as evi-
dence of infection as well. Cultures are
necessary to differentiate MAC from tuber-
culosis. Treatment with combinations of
medications including rifampin or rifabutin,
ethambutol, ciprofloxacin, amikacin, and
clarithromycin or azithromycin have been
used with some success. Ultimately, the
only long-term effective strategy for control-
ling MAC disease relies on immune
restoration with HAART.
Parasitic causes of diarrhea
Common parasitic causes of diarrhea
include Cryptosporidium, Microsporidium
and Entamoeba histolytica. Crypto-
sporidium parvum is found worldwide in
drinking water that has been contaminated
by fecal cysts from grazing animals. Water
that is drawn from wells is less likely to be
affected. Heat and chlorine are not effec-
tive against Cryptosporidia. Illness due to
Cryptosporidium can last for months in
those who are HIV-infected, leading to
dehydration, electrolyte abnormalities and
wasting. Treatment of Cryptospridium is
only of marginal benefit. The non-
absorbable aminoglycoside paromomycin
is most commonly used for treatment in this
country. 
Microsporidia species are spore-forming
parasites that can cause a wide variety
of clinical syndromes among those
who are HIV-infected. The microsporidial
organisms Enterocytozoon bieneusi and
Encephalitozoon intestinalis can cause
diarrhea and wasting, and albendazole can
be effective for treatment. 
In most cases, E. histolytica is a colonizer
and does not cause symptoms; however,
some strains of E. histolytica can lead to
cramping, abdominal pain, painful bowel
movements, and bloody stools.  E. histolyt-
ca is diagnosed by stool examination or
blood serology. Treatment for symptomatic
disease (i.e. invasive disease) is metron-
idazole 750mg 3X/day for 10 days. There is
disagreement as to the benefit of treating
those who are asymptomatic but have
b en demonstrated to pass cysts. If the
goal is to eradicate cysts from the intestinal
lumen, the recommended treatment is
iodoquinol 650mg 3X/day for three weeks.  
Giardia lamblia is an enteric protozoan with
a worldwide distribution that causes acute
and chronic diarrhea throughout the world.
Giardiasis can be transmitted through
water and person-to-person by the fecal-
oral route. Most of those who ingest
Giardia cysts will not become infected. Of
those who are infected, some will become
asymptomatic cyst passers while others
will develop diarrhea. Symptoms can
include cramps, diarrhea, bloating, flatu-
lence, and weight loss. Giardia is diag-
nosed by the detection of cysts or tropho-
zoites in the stool by direct examination or
a tigen assay. Treatment is generally
metronidazole at a dose of 250 mg 3X/day
f r five days.
Viral causes of diarrhea
Diarrhea due to rotavirus or other viral
agents is relatively common but is usually
self-limited. In most cases these illnesses
are of short duration and require no specif-
ic diagnostic or therapeutic intervention
other than oral fluids and over-the-counter
antimotility agents.  
In those with advanced immunosuppres-
sion (typically CD4 counts of <50/mm3)
CMV can lead to colitis, but since the intro-
duction of HAART, the incidence of active
CMV disease has fallen dramatically in the
U.S. Diagnosis is usually made by flexible
sigmoidoscopy or colonoscopy. CMV can
lead to areas of erythema, ulceration, and
hemorrhage. Histologic examination of
biopsy specimens reveals intranuclear
inclusion bodies in infected epithelial,
endothelial, or smooth muscle cells. 
Acute treatment of CMV colitis is ganci-
clovir IV 10-15mg/kg/day in two to three
divided doses. Foscarnet is also effective
at a dose of 180 mg/kg/day IV in two or
three divided doses. In the absence of
immune restoration, active disease com-
monly recurs. In the event of relapse,
retreatment followed by daily maintenance
therapy is indicated. The only long term
Gastrointestinal Complications...
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most common cause of mor-
bidity and mortality among
those who are HIV-infected.”
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effective treatment for CMV is HAART-
induced immune restoration.  
Fungal causes of diarrhea
Disseminated fungal diseases are uncom-
mon causes of diarrhea in those who are
HIV-infected. Histoplasmosis can involve
the gastrointestinal tract, leading to diar-
rhea, fever, pain, and weight loss.
Diagnosis can be made by the detection of
intracellular budding yeast in colonic biop-
sy specimens. The histoplasmosis urinary
antigen is very useful for diagnosing this
infection and for monitoring therapy. Initial
therapy of disseminated histoplasmosis is
generally amphotericin B, followed by
maintenance with either amphotericin B or
itraconazole. Maintenance must be contin-
ued lifelong, unless HAART leads to signif-
icant sustained immune reconstitution. 
Anorectal Disease
Anorectal disease is very common among
those who are HIV-infected. Oftentimes
patients will not divulge that they have
anorectal symptoms or lesions. Clinicians
should routinely ask patients about anorec-
tal symptoms, and periodically perform a
visual inspection of the external anal area.  
Herpes Simplex Virus
Both HSV1 and 2 commonly cause anorec-
tal disease. HSV infection can also lead to
urinary symptoms, impotence, and sacral
paresthesias. In HIV-infected patients who
present with perianal ulcerative lesions or
fissures, the most common cause is HSV.
Patients should be treated with oral acy-
clovir or valacyclovir for ten to fourteen
days. Lesions that fail to respond should be
cultured for HSV, and if positive, sent for
susceptibility testing. Lesions that are acy-
clovir resistant can be effectively treated
with intravenous foscarnet. Relapses are
quite common but can be decreased in fre-
quency by the use of suppressive therapy
with acyclovir at a dose of 200-400mg
2X/day. 
Gonorrhea, syphilis, and chlamydia
Patients who are infected with Neisseria
gonorrhoeae and/or Chlamydia trachoma-
tis can present with symptoms that include
anal discharge, pain, tenesmus, and bleed-
ing. Cultures of rectal swabs and urine lig-
ase chain reaction (LCR) for Gonorrhea or
Chlamydia infection can be useful in mak-
ing the diagnosis. Ceftriaxone 250mg IM
for one dose, followed by either doxycy-
cline 100mg 2X/day for seven days or
azithromycin 1200 mg for one dose is rec-
ommended for both anorectal gonorrhea
and chlamydia. Syphilis can also cause
painful or painless ulcers of the anal
mucosa or rectum. The diagnosis is usual-
ly made clinically in conjunction with a
serum RPR test.  
Condyloma
Warts, caused by human papillomaviruses,
(HPV) are commonly found in the perianal
area. Lesions can be either flat or cauli-
flower-shaped, are usually multiple and
asymptomatic but can cause itching or
bleeding. Small warts can spontaneously
resolve, and removing visible warts does
not reliably eradicate the causative virus.
HPV can frequently be isolated from indi-
viduals who have no visible lesions.
Regardless of the type of treatment, warts
commonly recur. Some strains of HPV are
associated with anal cancer, and biopsy
should be performed in those with exten-
sive lesions and patients who do not
respond to therapy. Data have been pre-
sented this past year concerning the devel-
opment of therapeutic and preventive vac-
cines for HPV. These vaccines hold great
promise for reducing the risk for anal and
genital lesions and most importantly for
decreasing the likelihood of cervical and
anal carcinoma. Although beyond the
scope of this article, there is a growing
body of literature that discusses the poten-
tial role of anal pap smears in the early
diagnosis of malignancy. Some of the most
commonly used treatments for warts are
outlined in Table 1.
Disclosures:
*Nothing to disclose.
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TABLE 1: Commonly Used Treatments for Warts 
Treatment
Bichloroacetic
acid (BCA) or
trichloroacetic
acid (TCA).
Podophyllin
10% to 25%
resin
Podofilox
0.5% gel or
solution
Imiquimod 5%
alpha-
interferon 
surgical 
excision
cryotherapy
How Administered
By clinician, 
solution applied in
several thin coats to
wart(s). Dries as a
white "frost"
By clinician, small
amount applied to
each wart, air dry 
By patient, applied
with an applicator/
swab to visible 
warts
By patient, applied 
in thin film to warts
at bedtime. 
By clinician, 
intralesional 
injection
By clinician, with
scalpel, scissors,
laser, or 
electrocautery
By clinician, warts
are frozen with 
liquid nitrogen
Frequency
Q 1-2 weeks,
up to 6 
applications
Q week until
warts are gone
BID for 3 
consecutive
days each 
week
Three times
weekly for up 
to 16 weeks.
Depends upon
response
Once
Q 1-2 weeks 
for 3-6 
treatments
Side Effects
burning
pain, 
ulceration,
scarring
pain
redness, 
pain, or 
ulceration
fever, myal-
gia, flu-like
symptoms 
pain, 
infection
pain, 
blistering,
scarring
Comments
Don't reapply if the
area is not healed
from prior treat-
ment.
Wash off several
hours after applica-
tion to decrease
toxicity and sys-
temic absorption.  
No need to wash
off. Not for use in
pregnancy
Wash off in 
morning.   
Not for use in 
pregnancy
Requires local or
general anesthesia
Most effective with
several freeze-thaw
cycles for 10-25
seconds per freeze
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Bethany Weaver*, D.O., M.P.H., Acting Instructor of Medicine, University of Washington Center for AIDS & STD Research (CFAR) and Northwest
Correctional Medicine Education Program. 
Case Study: Diarrhea in a Patient with AIDS
CASE: A 43-year-old male inmate with stage C3 HIV/AIDS presents with loose, watery stools, abdominal cramping, sweats, fevers,
poor appetite (2 months) and 15 lbs weight loss.  He is taking Combivir one tablet bid and Nelfinavir 1000mg tid, and trimethoprim/sul-
famethoxazole for secondary pneumocystis carinii pneumonia (PCP) prophylaxis. He reports good adherence, with an undetectable
viral load and a CD4 count of 100 cells/mm3.  He was diagnosed with HIV and PCP when he entered the U.S. from Mexico one year
ago, at which time he had a CD4 count of 2 cells/mm3 and “high” HIV-1 viral load.  He is an injecting  drug user and has sex only with
men.  He reports unprotected sex with two anonymous partners two to three months ago when he traveled to Mexico.  He weighs 130
lbs and is afebrile with normal blood pressure, genital and neurologic exam. His pharynx was without thrush; there was no scleral
jaundice, some temporal wasting, no rash, abdominal tenderness, organomegaly, lymphadenopathy, or peripheral edema.  
Q:  What is the differential diagnosis?
A: Opportunistic pathogens such as disseminated Mycobacterium
avium complex (MAC), PCP, and cytomegalovirus (CMV), should
be considered, though PCP does not typically cause GI disease.
He is also at risk for Entamoeba histolytica, Dientamoeba fragilis,
Blastocystis hominis, Giardia lamblia, Campylobacter jejuni,
Shigella spp, Salmonella spp, C. difficile, syphilis and herpes sim-
plex virus. Because of recent travel to Mexico, Escherichia coli,
Vibrio parahaemolyticus, Yersinia spp, rotaviruses, and Norwalk-
like viruses are also in the differential. Additionally, this inmate
could have diarrhea and wasting from HIV itself. It is not likely that
Nelfinavir is causing his diahhrea as he tolerated this drug for nine
to ten months and only recently developed diarrhea. Though the
Nelfinavir may not be the cause of the diarrhea, it may be aggra-
vating it.  
Q:  What tests should you perform/order?
A: Stool samples should be sent for for WBCs, to help differenti-
ate inflammatory from non-inflammatory causes of diarrhea (histo-
ry of watery as opposed to bloody diarrhea suggests non-inflam-
matory).  Stool samples should also be sent for culture for enteric
pathogens, smear for ova and parasites, Giardia antigen,
Clostridium difficile toxins A and B, and acid-fast bacilli (AFB)
smear and culture.  Tests for ova and parasites, C.difficile toxins,
and smears for AFB should be repeated twice, as it often takes
multiple evaluations before some of these pathogens are detected.
Blood should be sent for AFB culture and routine bacterial culture.
If there is no temporal association of the onset of diarrhea with anti-
retroviral therapy and the stool and blood studies are negative, the
next step in the evaluation is a colonoscopy. The highest yield for
colonoscopy is typically in patients with fever, weight loss, and a
CD4 count of fewer than 200 cells/mm3.
Concentrated exam of the stool showed many cysts of Giardia
lamblia and Entamoeba histolytica. This diagnosis should be
reported to the local public health department.  Many Entamoeba
coli cysts, many Endolimax nana cysts, and moderate Iodamoeba
butschlii cysts were also seen.  On auramine stain, moderate cryp-
tosporidia were detected. 
Q:  What treatment(s) should you offer this inmate? Are there
drug-drug interactions to consider?
A: Endolimax nana, Entamoeba coli, and Iodamoeba butschlii are
nonpathogenic commensals and as such require no treatment.
They are however markers of exposure to human feces and are
often found in patients who are also infected with pathogenic
organisms.  Giardia and Entamoeba histolytica can cause invasive
disease and should generally be treated. 
The drug of choice for giardiasis is metronidazole 250 mg tid for 7
days, which also has activity against E. histolytica.  Unfortunately,
th re are no reliable therapies for Cryptosporidiosis, though paro-
momycin or nitazoxanide may have activity and offer benefit.
Supportive care with hydration and nutrition, as well as institution
of an effective antiretroviral regimen, are crucial aspects of care
since improvement in the immune system often helps eradicate the
infection. In immunocompetent hosts, cryptosporidiosis is usually
self-limited. It may be in this inmate's best interest to change his
medications to a more potent antiretroviral regimen in an effort to
improve his T cell response and minimize his gastrointestinal side
effects. If the regimen is not changed, the dose of Nelfinavir should
be changed to 1250mg po bid as this dose is easier to take and is
associated with fewer loose stools compared to the tid dose. There
are no known drug-drug interactions between metronidazole, paro-
momycin, or nitazoxanide and the antiretrovirals he is currently
tak ng. There is a drug-drug interaction between the oral solution
form of the protease inhibitor amprenavir and metronidazole. This
is not true for the capsule formulation of amprenavir.  
Q:  What infection-control measures should you recommend?
: To minimize secondary transmission to others via fecal-oral
spread, it is important to educate the inmate and staff on good
hand-washing skills, particularly before and after meals and use of
the restroom. He should be excluded from any kitchen work until
his diarrhea has resolved and his stool is cleared of all organisms.  
Disclosures:
*Stockholder: Pfizer
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A university-based ID consultant familiar with prisoners and
detainees is puzzled. After initial success, the patient, a 29 year-
old Haitian male, now has a viral load of 185,000. In accented
English, the patient states that he has taken all his medications. A
quick check of three months of Medication Administration
Records shows that all his antiretrovirals (ARVs) are given under
Directly Observed Therapy (DOT), and that fewer than three per-
cent of doses were missed.
When first seen by the consultant, the case
had seemed simple. The prisoner said that
his injecting drug use started a decade ago,
and that he had never taken antiretroviral
therapy before. The prison family practition-
er had obtained a positive HIV antibody, a
CD4 count of 20, and a viral load of 15,000.
The consultant recommended Didanosine
(ddI) EC, Atazanavir, and Lamivudine (3TC).
For the first two months, the patient’s viral
load was undetectable and his CD4 count
was rising. However, four months into the
therapy, viral loads were increasing. The
consultant ordered a genotype, which
showed the presence of mutations K65R,
I50L, and M184V, suggesting that all three
drugs were failing. What went wrong?
The consultant had the foresight to call the
referring prison practitioner to discuss this
patient's circumstances, and a number of facts emerged.
Although both the consultant and primary care doctor had edu-
cated the patient on the need to take the ddI EC one hour before
breakfast, and the Atazanavir during the meal, the patient found it
too difficult to comply with these instructions in the correctional
setting. In his segregation unit, breakfast was at 4:30 a.m. on
weekdays and 6:00 a.m. on Saturdays and Sundays. ART and
other DOT medications were administered cell by cell by a nurse
who began most days at 6:00 a.m. and finished at 8:00 a.m. or
later. Depending on which end of the wing the nurse started, this
inmate may receive his ART as early as 6:00 a.m. or as late as
8:00 a.m. The inmate had decided to take all his medications
together, usually after breakfast. To compound the problem, he
ha  a chronically upset stomach and resorted to purchasing vari-
able amounts of antacids from the Commissary. As a result,
antacids and the Didanosine EC buffering were inactivating the
Atazanavir. A valuable opportunity to stabilize the patient with his
first regimen had been lost.
This case illustrates two points: the well
known necessity to time certain ART with
regard to meals, and the challenges of so
doing in the correctional environment. To suc-
ceed, both consultants and primary care
givers need to understand the totality of the
patient circumstances and proceed accord-
ingly. The National Institutes of Health has
published guidelines entitled Use of
Antiretroviral Agents in HIV-infected Adults
and Adolescents. These guidelines available
at www.aidsinfo.nih.gov provide useful infor-
mation concerning drug-drug interactions and
antiretroviral medications that are no longer
recommended for the treatment of HIV-infect-
ed patients. Practitioners should question
patients extensively concerning the variability
of pill calls, DOT lines and meals. In some
cases, it may not be prudent to prescribe
drugs with strict meal timing requirements. In
other situations, a light snack may be provid-
 so the inmate can time his meal to scheduled ART according-
ly. Finally, even in DOT systems, it may be necessary to make an
exception for certain medications to be self-administered, so as to
permit the proper timing with respect to food. Open lines of com-
munication with patients on ART are a necessity. It used to be
said that, in ART, the best medication regimen is the one that the
patient will take. The newer version now reads: the best medica-
tion regimen is the one that the patient will take at the right time.
Disclosures:
*Nothing to disclose.
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Joseph Paris*, MD, CCHP Georgia Department of Corrections
Spotlight: Keys to Successful HIV Management in Corrections- 
Knowing the patient and the prison/jail environment
Case Study: Diarrhea in Patients with
AIDS...
(continued from page 6)
“ It used to be said that, 
in ART, the best 
medication regimen 
is the one that 
the patient will take. 
The newer version 
now reads: the best 
medication regimen 
is the one that 
the patient will take 
at the right time.”
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Diarrhea is defined as loose, watery stools occurring more than three times in one day. The average adult has a bout of diarrhea
four times per year. It is a common problem that usually lasts a day or two and goes away on its own without any special treatment.
Prolonged diarrhea can be due to a variety of pathogens as outlined in the HEPPigram below. 
Keep in mind that patients may use the word diarrhea to describe anything from an upset stomach, to occasional watery stools, to
frequent voluminous bowel movements. Sometimes, patients may require observation to allow objective documentation of symp-
toms. Reliably obtaining stool specimens in the correctional setting can be challenging and may require a brief stay in the infirmary.
HEPPigram: Evaluation of Diarrhea in Patients with HIV
Consider medication-induced diarrhea. 
If possible, change medications accordingly.
Patient is afebrile, not dehydrated, 
and has no weight loss
Diarrhea duration >1 week, or patient is febrile, 
has weight loss, or has blood in stool
Symptoms resolve Symptoms don't
resolve
Diagnosis made No diagnosis made
Diagnosis made No diagnosis made
Treat Flexible sigmoidoscopy or
colonoscopy with bx. 
Specimens should be cultured 
and stained for protozoa, 
CMV, HSV, and mycobacteria
Treat Repeat above 
cultures and stains, 
consider upper endoscopy 
with small bowel biopsy, 
consider malabsorption studies
Observe, oral hydration, 
antiperistaltic medication
Stool culture x 1 for Campylobacter, Salmonella, Shigella, E. coli 0157H7;
stool for ova and parasites x 3.
If febrile, obtain blood culture for bacteria and mycobacteria (MAC)
If recent antibiotics, stool for C. difficile toxin x 3
Joseph Bick, MD, Chief Medical Officer, California Medical Facility, California Department of Corrections
Helping Communities Build
Leadership (HCBL) 
April 16-18, 2004
Las Vegas, NV
Sponsored by the National
Association of People with AIDS
(NAPWA). Focuses on community
health care planning; 
HIV/AIDS Prevention  
Call: Ca'Tina Perkins-Gibson 
at 202.464.5682
Email:cperkins@napwa.org. 
Visit: www.napwa.org
Supporting Networks of HIV
Care Project Regional 
Intensive Training 
April 23, 2004 
Jackson, MS
Covers case management/
administration, health care 
delivery, HIV-positive persons, 
HIV test-related counseling,
minorities, primary care.  
Call: 800.861.5640
Fax: 202.232.6750 
Visit: www.hivta.org
38th Educational Conference:
Advocacy and Science: 
Tools for TB Control 
in the 21st Century 
April 29-30, 2004 
Anaheim, CA
Enhancing tuberculosis (TB) 
control efforts in California by
building TB program capacity
through advocacy efforts and
access to scientific advances. 
Email: tbcenter@
nationaltbcenter.edu 
Visit: www.ctca.org/confinfo.htm
The Future of Health Promotion
and Health Education:
Transforming Vision into Reality 
May 5-7, 2004 
Orlando, FL
Training, networking opportunities,
and a wealth of info that all public
health professionals need to 
continue quality public health pro-
motion and education initiatives. 
Visit: www.dhpe.org/
nationalconference
NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency - Chicago
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
Save the 
Dates
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CROI Update Part II:
Continued from HEPP Report, March 2004
Rick Altice*, MD, Director, HIV in Prison
Program, Yale University AIDS Program
Comparison of Two Boosted PIs in Heavily
ART-experienced patients
BMS-045 is a randomized controlled trial of the
once-daily boosted atazanavir (ATV/r) vs. twice-
daily boosted lopinavir (LPV/r).  A third arm with
the dual PI combination of ATV+SQV was also
used, but for a number of reasons, was clearly
inferior to either of the arms. Eligibility for this
study included having failed at least two ART reg-
imens and at least one regimen from two different
classes.  All subjects were given tenofovir +
another NRTI after the first two weeks of the
boosted PI.  Patients were similarly matched on
demographic characteristics, prior AIDS (28%),
median VL on HAART (4.45 log) and CD4 (~300)
and prior type and duration of HAART use (prior
PI use ~2.5 years).  With regard to 48 week out-
comes, both arms resulted in similar reductions in
VL (~1.9 log), increases in CD4 (~120 cell/mL)
and using an intent-to-treat analysis (ITT),
VL<400 (56%) and VL<50 (~39%).  Efficacy was
dependent on the number of PI mutations pre-
sent at baseline and similar between the two
groups. Subjects who had fewer than four major
PI mutations were more likely to have a virologi-
cal response compared to those with four or more
mutations.  Unlike previous studies with LPV/r,
however, the investigators did not analyze
whether a similar break point of six mutations
portended a better outcome between the two
comparison arms.  Withdrawal due to adverse
events in both groups was low (5%), however
compared to LPV/r, there was less diarrhea (3%
vs. 11%) and more jaundice (6% vs. 0%) in the
ATV/r arm.  In the ATV/r arm, the proportion of
subjects who experienced bilirubin >2.5 mg/dl
and >5.0 mg/dl was 39% and 9%, respectively.
No patient withdrew from the study for hyper-
bilirubinemia and was not associated with
changes in hepatic transaminases. Use of
antidiarrheal agents was significantly less in the
ATV/r (6%) arm compared to the LPV/r (24%)
arm.  Anxiously awaited was whether boosted
ATV would continue to maintain a lipid benefit in
subjects. Compared to LPV/r, ATV/r resulted in
lower mean changes in cholesterol (-8% vs. +6%)
and triglycerides (-4% vs. +30%) even after cen-
soring data for those who started lipid-lowering
agents.  Clinically, the ATV/r group was less like-
ly to initiate lipid-lowering therapy than the LPV/r
group (8% vs. 19%).  In summary, once-daily
ATV/r has similar efficacy to the standard twice-
daily LPV/r in heavily pre-treated subjects with
drug-associated clinical diarrhea and hyperlipi-
demia. ATV/r does, however, result in increased
bilirubin levels that is not associated with liver
toxicity.  
Standard LPV/r Dosing vs. Once-Daily
Treatment 
In a study of 190 ART-naïve patients, randomized
in a 3:2 schema and who received the NRTI
backbone of once-daily emtricitibine (FTC) +
tenofovir (TDF), subjects received either once-
daily (six Kaletra all at once) or twice-daily (three
Kaletra twice daily) LPV/r.  The subjects had sim-
ilar background characteristics, including mean
baseline CD4 = 216 (45% with CD4 <200) and
VL=4.8 log (~65,000 copies/mL). Both groups
h d an impressive increase in CD4 (~185) and
VL was assessed using ITT and as-treated (AT)
approaches.  Compared to the standard twice-
daily therapy, the proportion with a VL<50 at 48
weeks in the once-daily arm was 70% vs. 64%
using ITT and 90% vs. 85% using AT analysis,
respectively (no significant differences). Though
total discontinuations for the study was no differ-
e t between groups (19% vs. 25%), it was higher
han found in other studies of Kaletra.
Discontinuation due to adverse side effects, how-
ever, was higher in the once-daily group (12% vs.
5 ); diarrhea was also significantly greater in the
once-daily group (16% vs. 5%).  Mean triglyc-
eride changes did not differ between the groups
(+82 mg/dL vs. +76 mg/dL).  In sum, this provides
supportive data for the use of once-daily LPV/r in
ART naïve subjects for up to 48 weeks, particu-
larly at a time when simplified regimens are pre-
ferred in correctional settings.  
Disclosures:
*Consultant and Speaker's Bureau:  Agouron,
Abbott, BMX, Boehringer Ingleheim, DuPont,
Inside News
Resources
General Information on diarrhea:
http://digestive.niddk.nih.gov/ddiseases/pubs/
diarrhea/index.htm#whatis
Information on diarrhea associated with HIV:
www.aids.org/factSheets/554-Diarrhea.html
The CDC's 2002 treatment guidelines for 
genital warts and other STDs:
www.cdc.gov/std/treatment
Guidelines for Using Antiretroviral Agents
Among HIV-Infected Adults and Adolescents:
www.cdc.gov/mmwr/preview/mmwrhtml/
rr5107a1.htm
Recommendations and tables on HIV:
www.hivguidelines.org/public_html/center/
clinical-guidelines/adult_hiv_guidelines/
supplemental_pages/other/pdf/
gastro-recandtab.pdf
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through October 31, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Most mild cases of thrush can be treated effectively with:
a) intravenous amphotericin
b) oral fluconazole
c) nystatin or clotrimazole
d) oral azole
2. A patient who presents with odynophgia, retrosternal pain,
nausea, emesis and tracheoesophageal fistula most likely has:
a) candida esphogitis
b) esophageal herpes simplex virus 
c) cytomegalovirus (CMV)
d) none of the above
3. Drugs that commonly cause a change in bowel motility
include:
a) psychiatric medications
b) some antiretroviral and cardiac medications
c) antacids
d) all of the above
4. In an HIV-infected patient who presents with diarrhea that lasts
for more than one week, it is recommended to send three sepa-
rately collected specimens for ova and parasite analysis. 
a) True
b) False
5. Bacteremic disease in those with HIV infection is most likely a
result of:  
a) Salmonella infection
b) Shigella infection
c) Campylobacter infection
d) Mycobacterium avium complex (MAC)
e) Areomonas infection
6. An effective, long-term strategy for controlling MAC, CMV, and
histoplasmosis is:
a) amphtericin B or itraconazole
b) foscarnet
c) immune reconstitution
d) none of the above
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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